Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
TRIUMPH-4 (28.7% weight loss, knee OA population, December 2025), TRIUMPH-1 (28.3%, general obesity, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c, 16.8% weight loss, June 2026), TRIUMPH-2 (20.8% weight loss, obesity + diabetes, July 23, 2026), and TRIUMPH-3 (22.6% weight loss, obesity + cardiovascular disease, July 23, 2026) have all reported positive results
Cardiovascular Risk Reduction: It is also approved to reduce the risk of major adverse cardiovascular events (like cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease who are obese or overweight
3 Growing Body of Evidence for Benefits of Lower Blood Pressure Targets The table below shows the blood pressure categorization thresholds based on the 2017 consortium guidelines
An important clinical paradox: elevated serum B12 can sometimes coexist with functional B12 deficiency
